Newborn blood spot screening for galactosemia, tyrosiemia type I, homocystinuria, sickle cell anemia, sickle cell/beta-thalassemia, sickle cell/hemoglobin C disease and severe combined immunodeficiency

Institute of Health Economics

Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors' objectives
This STE report examines the safety, screening accuracy, therapeutic efficacy/effectiveness, cost-effectiveness, budget impact, and health system readiness of newborn screening for seven conditions (galactosemia, tyrosinemia type I, homocystinuria, sickle cell anemia, sickle cell/beta-thalassemia, sickle cell/hemoglobin C disease, and severe combined immunodeficiency), contextualized to the Alberta setting.

Final publication URL

Additional data URL
http://www.health.alberta.ca/initiatives/health-evidence-reviews-list.html

Indexing Status
Subject indexing assigned by CRD

MeSH
Humans; Galactosemias; Hemoglobin C Disease; Hemoglobin SC Disease; Homocystinuria; Infant, Newborn; Neonatal Screening; Severe Combined Immunodeficiency; beta-Thalassemia

Language Published
English

Country of organisation
Canada

Province or state
Alberta

English summary
An English language summary is available.

Address for correspondence
Institute of Health Economics (IHE), #1200, 10405 Jasper Avenue, Edmonton, AB T5J 3N4, Canada Email: info@ihe.ca

AccessionNumber
Date abstract record published
16/11/2016